New drug cocktail aims to boost pancreatic cancer surgery success

NCT ID NCT06587061

Recruiting now Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether adding the experimental drug HRS-4642 to standard chemotherapy (gemcitabine and albumin-bound paclitaxel) can help shrink pancreatic tumors before surgery and prevent recurrence afterward. About 30 adults with resectable or borderline resectable pancreatic cancer will receive the combination, then surgery, then more treatment. The study will measure safety, tumor response, and how many patients achieve complete tumor removal.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-4642 combined with gemcitabine and albumin-bound paclitaxel
What this could lead to: If successful, this could lead to a more effective pre- and post-surgery treatment for pancreatic cancer, potentially improving survival and surgical outcomes.
What could go wrong: This is an early Phase 2 trial with only 30 participants, so results may not apply broadly. The combination may cause significant side effects, and it is not yet known if it will improve long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Ruijin Hospital Shanghai Jiaotong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.